Sage Journals: Discover world-class research

Abstract

Interleukin 17F (IL-17F) is an inflammatory cytokine that plays an important role in autoimmune disease by inducing the expression of multiple chemokines, cytokines, and adhesion molecules. In vitro functional analysis revealed that IL-17F rs763780 polymorphism is associated with IL-17 expression and activity. Thus, considering the abnormal percentage of T helper 17 cells in patients with primary immune thrombocytopenia (ITP), we speculated there was a possible association between the IL-17F rs763780 polymorphisms and genetic susceptibility to ITP in a Chinese Han population. A total of 165 patients with ITP and 149 healthy controls were included in this study, and IL-17F rs763780 polymorphisms were analyzed by a polymerase chain reaction–restriction fragment length polymorphism system. The results showed that the frequency of the IL-17F rs763780 G allele in total patients with ITP or patients with chronic ITP was significantly lower than in normal controls (total ITP 3.6% vs controls 7.7%, P = .026; chronic ITP 3.5% vs controls 7.7%, P = .031). However, no significant difference in genotype frequencies was found among total patients with ITP, patients with chronic ITP, and normal controls. We further analyzed the association of IL-17F polymorphisms with clinical parameters of patients with ITP, and no association revealed between gene distribution and first onset age, clinical therapy response to glucocorticoids, or disease course. What’s more, an evident discrepancy with allelic frequencies was observed between female patients with ITP and gender-matched controls. In conclusion, IL-17F rs763780 polymorphisms may be associated with the development of ITP in a Chinese Han population.

Keywords

primary immune thrombocytopenia interleukin 17F polymorphism genetic susceptibility

Introduction

Primary immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by decreased platelet count resulting from increased platelet destruction and insufficient platelet production.¹ The pathogenesis of ITP is not completely clarified but it is widely accepted that more than one mechanism could contribute to this disease, such as autoreactive B lymphocytes secreting antiplatelet antibodies, T-cell mediated platelet lysis, and reduced numbers and poor functions of circulating regulatory T cells.^2,3

Autoantibody production by B cells requires the help of autoreactive T cells, and the platelet-reactive CD4⁺ T cells are therefore involved in ITP by assisting the production of pathogenic antiplatelet autoantibodies. Based on the cytokine profiles, CD4⁺ helper T cells are traditionally classified into several subsets among which are T helper 1 (Th1), T helper 2 (Th2), and T helper 17 (Th17). The balance among these 3 subsets has been implicated in the regulation of many immune responses and is known to be impaired in various autoimmune diseases. An increased Th1/Th2 ratio in the peripheral blood has been proposed to correlate with disease activity in ITP.^4
–6 Moreover, upregulated Th17 cells may also play a role in the pathogenesis of ITP.^7
–9

Interleukin 17F (IL-17F) is discovered to share a strong homology to IL-17A. They are the members of the IL-17 cytokine family responsible for the pathogenic activity of the Th17 cells.¹⁰ Binding IL-17 to its receptor initiates signaling pathways which induce the production of proinflammatory cytokines and chemokines and induce the recruitment of neutrophils.^11,12 For the critical proinflammatory effect, IL-17F level were elevated and showed a statistically significant correlation with disease activity in patients with systemic lupus erythematosus.¹³ In addition, increased IL-17F levels were also found in patients with rheumatoid arthritis¹⁴ and asthma.¹⁵ In our previous study, we found IL-17F messenger RNA was increased in splenocytes of ITP mice than in controls, which suggested that IL-17F may also play a role in ITP.¹⁶

Interleukin 17F encoded gene is mapped to the human chromosome arm of 6p12.2, which consists of 3 exons and 2 introns.¹⁷ IL-17F rs763780 polymorphism is located within the coding region of IL-17 F gene and causes a His-to-Arg substitution at amino acid 161. In vitro functional analysis revealed that IL-17 expression and activity may be suppressed in carriers of the rare G allele.¹⁸ This polymorphism was reported to be associated with the development of some autoimmune disease among asthma,¹⁹ inflammatory bowel disease,^20,21 and multiple sclerosis.²² Recently, Saitoh et al²³ found that the IL-17F rs763780 G allele is significantly associated with the development of chronic ITP in a Japanese population. However, due to an ethnic disparity, the distribution of the IL-17F rs763780 polymorphism in Chinese population is still unknown. Considering the abnormal percentage of Th17 cells in patients with ITP, we speculated the IL-17F rs763780 polymorphisms were contributed to the genetic susceptibility to ITP. To further unveil the IL-17F rs763780 allele distribution and association with the risk for ITP in a Chinese Han population, we carried out this study.

Methods

Patients

One hundred and sixty-five patients with ITP and 149 geno- and sex-matched healthy controls were included in this study. Informed consent was obtained from the patients’ legal guardians or the patients themselves, and this study was approved by the hospital-based ethics committee. The diagnosis of ITP met the diagnostic criteria as described previously.²⁴ Primary immune thrombocytopenia was defined as thrombocytopenia (platelet count < 100 × 10⁹/L), normal or increased marrow megakaryocytes, and no secondary immune or nonimmune abnormalities that could account for the thrombocytopenic state. According to the age of first onset, the cases were further stratified into childhood ITP (onset age < 18 years) and adult ITP (onset age ≥ 18 years). In addition, most enrolled patients (n = 125) were treated with glucocorticoids (GCs), including methylprednisolone, dexamethasone, and prednisone. Other patients were received with nonimmunosuppressive treatments such as eltrombopag and recombinant human thrombopoietin. We also analyzed the response to GCs according to the response criteria of the ITP International Working Group.²⁴ A complete response (CR) is defined as any platelet count of at least 100 × 10⁹/L, and a response (R) was defined as any platelet count between 30 and 100 × 10⁹/L or at least doubling of the baseline count. No response (NR) was defined as any platelet count lower than 30×10⁹/L or less than doubling of the baseline count. All patients were followed up in the outpatient department for at least 12 months from diagnosis. And the patients were classified into newly diagnosed ITP if remission within 3 months, the patients were classified into chronic ITP if course of the disease was more than 12 months, and others were classified into persistent ITP .The characteristics of the patients are shown in Table 1.

Table 1.

The Characteristics of Patients With ITP and Normal Controls Enrolled in This Study.

Characteristics	Total ITP	Normal Controls
Number of patients	165	149
Gender (Male: female)	58:107	46:103
Age at diagnosis median (range), year	29 (2-79)
Child-onset ITP (age at diagnosis<18)	49
Adult-onset ITP (age at diagnosis≥18)	116
Disease course median (range), month	12 (0.2-480)
Number of patients treated with GCs	125
Clinical responses to GCs (number)
Complete response	69
Response	18
No response	38

Abbreviations: GCs, glucocorticoids; ITP, primary immune thrombocytopenia.

Extraction of Genomic DNA

Peripheral blood samples were collected in vacuum tubes containing 5% EDTA. Genomic DNA was isolated from peripheral blood using the Wizard genomic DNA purification kit (Promega, Madison, Wisconsin) according to the instructions.

Genotyping

Genotyping was performed using a polymerase chain reaction (PCR)–restriction fragment length polymorphism (RFLP) system. The PCR primers for amplification of the IL-17F rs763780 polymorphism were 5′-GTGTAGGAACTTGGGCTGCATCA AT-3′ (forward) and 5′-AGCTGGGAATGCAAACAAACT-3′ (reverse). The PCR reaction was performed in a final volume of 25 μL containing 50 ng of genomic DNA, 10 pmol of each primer, and 12.5 μL 2 × Premix Taq (Takara, Dalian, China). For PCR amplification, an initial denaturation at 94°C for 5 minutes was followed by 35 cycles at 94°C for 30 seconds, 58°C for 45 seconds, 72°C for 45 seconds, and a final extension at 72°C for 10 minutes. Cleavage was performed with restriction enzymes NIaIII (New England BioLabs, Ipswich, Massachusetts) according to the manufacturer’s protocols. Digested fragments were separated on 2% agarose gels, and RFLP bands were visualized by ethidium bromide staining under UV light. Reproducibility was confirmed by repeating analysis of a random selection of 10% of the cases and controls.

Statistics

Statistical analysis was performed using SPSS 16.0, and the Hardy-Weinberg equilibrium, genotype and allele frequencies were analyzed using the chi-square test or Fisher exact test in case of expected frequencies< 5. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated for each variable. P < .05 was considered as statistically significant.

Results

There were 165 patients with ITP and 149 normal controls included in current study. And most patients with ITP (n = 125) were treated with GCs. At our center, the routine usage of GCs for patients with ITP were methylprednisolone (0.8 mg/kg of body weight) or prednisone (1 mg/kg of body weight) for 2 to 3 months or dexamethasone 40 mg/d for 4 consecutive days (for adults patients).

The genotype of 165 patients with ITP and 149 normal controls were detected, and the genotype frequencies in controls and patients were in the Hardy-Weinberg equilibrium (both P > .05).

The genotype and allele frequencies of IL-17F in total patients with ITP and controls were summarized in Table 2. We first evaluated the IL-17F rs763780 genotype and allele frequencies in all patients with ITP and normal controls, the result showed that the frequency of allele G was significantly lower in total patients with ITP than in the control group. In addition, although IL-17F rs763780 GG genotype was only found in normal controls, the difference of genotype frequency between patients and normal controls did not reach statistic difference. Furthermore, the distribution of this polymorphism was compared between the adult/childhood ITP group and the control with no statistical difference found.

Table 2.

Distribution of the Genotype and Allele Frequencies of IL-17F rs763780 Site in all Patients With ITP and Controls.

	Total ITP, n = 165 (%)	Childhood ITP, n = 49 (%)	Adult ITP, n = 116 (%)	Control, n = 149 (%)	P Value	OR (95% CI)
Genotype
AA	153 (92.7)	46 (93.9)	107 (92.2)	128 (85.9)	.082^a	2.092 (0.991-4.416)^a
GA	12 (7.3)	3 (6.1)	9 (7.8)	19 (12.8)	.304^b	2.516 (0.717-8.831)^b
GG	0	0	0	2 (1.3)	.184^c	1.951 (0.857-4.437)^c
GA+GG	12 (7.3)	3 (6.1)	9 (7.8)	21 (14.1)	1.000^d	1.290 (0.334-4.983)^d
Allele
A	318 (96.4)	95 (96.9)	223 (96.1)	275 (92.32)	.026^a	2.216 (1.083-4.537)^a
G	12 (3.6)	3 (3.1)	9 (3.9)	23 (7.7)	.106^b	2.648 (0.778-9.021)^b
					.066^c	2.072 (0.939-4.569)^c
					1.000^d	1.278 (0.339-4.825)^d

Abbreviations: CI, confidence interval; OR, odds ratio; ITP, primary immune thrombocytopenia.

^aTotal ITP group compared with controls.

^bChildhood ITP group compared with controls.

^cAdult ITP group compared with controls.

^dChidhood ITP group compared with adult ITP group.

As a first-line therapy strategy, most of the enrolled patients (n = 125) received the GCs treatment, thus, we analyzed the association between IL-17F polymorphisms and the clinical responses to GCs treatment. However, no statistical differences were detected in genotypes and allelic frequencies between the CR + R and NR groups (Table 3).

Table 3.

Stratification Analysis of the Relation Between IL-17F rs763780 Site Polymorphism and Clinical Responses to Glucocorticoids in Patients With ITP.

	Complete Response + Response, n = 87	No Response, n = 38	P	OR (95% CI)
Genotype
AA	79 (90.8)	36 (94.7)
GA	8 (9.2)	2 (5.3)	.456	0.549 (0.111-2.714)
GG	0	0
GA+GG	8 (9.2)	2 (5.3)
Allele
A	166 (95.4)	74 (97.4)
G	8 (4.6)	2 (2.6)	.466	0.561 (0.116-2.705)

Abbreviations: CI, confidence interval; OR, odds ratio; ITP, primary immune thrombocytopenia.

In addition, based on the disease course after follow-up, we subdivided the patients into 3 groups: newly diagnosed, persistent, and chronic ITP. We then evaluated the genotype and allele distribution among each of these 3 subsets, and no differences were found (Table 4). However, the frequency of allele G was significantly lower in chronic ITP groups than in the control group, In detail, the G allele frequency was 3.5% in patients with chronic ITP versus 7.7% in controls (P = .031, OR = 2.333, 95% CI =1.059-5.136)

Table 4.

Stratification Analysis of the Relation Between IL-17F rs763780 Site Polymorphism and Disease Course of Patients With ITP.

	Newly Diagnosed, N = 12	Persistent, N = 23	Newly Diagnosed + persistent, n = 35	Chronic, n = 130	P	OR (95% CI)
Genotype
AA	10 (83.3)	22 (95.7)	32 (91.4)	121 (93.1)	.227^a	0.371 (0.071-1.961)^a
GA	2 (16.7)	1 (4.3)	3 (8.6)	9 (6.9)	.645^b	1.636 (0.197-13.569)^b
GG	0	0	0	0	.739^c	0.794 (0.203-3.102)^c
GA+GG	2 (16.7)	1 (4.3)	3 (8.6)	9 (6.9)
A	22 (91.7)	45 (97.8)	67 (95.7)	251 (96.5)	.236^a	0.394 (0.080-1.939)^a
G	2 (8.3)	1 (2.2)	3 (4.3)	9 (3.5)	.650^b	1.614 (0.199-13.049)^b
					.744^c	0.801 (0.211-3.041)^c

Abbreviations: CI, confidence interval; OR, odds ratio; ITP, primary immune thrombocytopenia.

^aNewly diagnosed ITP group compared with chronic ITP group.

^bPersistent ITP group compared with chronic ITP group.

^cNewly diagnosed + persistent ITP group compared with chronic ITP group.

As shown in Table 5, an evident discrepancy with allelic frequencies was observed between female patients with ITP and gender-matched controls. However, no differences was detected in genotypes between these 2 groups. In addition, no statistical differences were detected in genotypes and allelic frequencies between the male cohorts and between female controls and male controls.

Table 5.

Stratification Analyses of IL-17F rs763780 Site Polymorphism with Gender in Patients with ITP and Normal Controls.

	Control		ITP		P value	OR (95% CI)
	Female, n = 103 (%)	Male, n = 46 (%)	Female n = 107 (%)	Male n = 58 (%)	P value	OR (95% CI)
Genotype
AA	89 (86.4)	39 (84.8)	101 (94.4)	52 (89.7)	.792^a	1.141 (0.427-3.047)^a
GA	13 (12.6)	6 (13.0)	6 (5.6)	6 (10.3)	.347^b	1.942 (0.597-6.321)^b
GG	1 (1.0)	1 (2.2)	0	0	.061^c	0.378 (0.139-1.024)^c
GA+GG	14 (13.6)	7 (15.2)	6 (5.6)	6 (10.3)	.456^d	0.643 (0.200-2.065)^d
Allele
A	191 (92.7)	84 (91.3)	208 (97.2)	110 (94.8)	.672^a	1.213 (0.495-2.970)^a
G	15 (7.3)	8 (8.7)	6 (2.8)	6 (5.2)	.356^b	1.891 (0.596-6.001)^b
					.035^c	0.367 (0.140-0.966)^c
					.313^d	0.573 (0.191-1.714)^d

Abbreviations: CI, confidence interval; OR, odds ratio; ITP, primary immune thrombocytopenia.

^aFemale control group compared with male control group.

^bFemale ITP group compared with male ITP group.

^cFemale control group compared with female ITP group.

^dMale control group compared with male ITP group.

Discussion

Although ITP was previously thought to be Th1-cell driven, it is now recognized that a distinct lineage of effector T cells, Th17 cells, is also involved in the development of ITP. Recently, more and more researchers found the circulating percentage of Th17 was markedly higher in patients with ITP than in normal controls.^9,8,25,26 However, some groups argued that Th17 cells count did not differ between patients with ITP and normal controls.^27,28 These differences could be due to the heterogenicity of ITP and sensitivity of the technique used. Besides Th17, Hu et al found that the number of Tc17 (defined as CD3+CD8+IL-17+) was significantly increased in newly diagnosed patients but not in patients who had CR, which indicated the importance of Tc17 in the development of ITP. Moreover, the percentage of Tc17 in patients with ITP was decreased with the addition of dexamethasone in vitro, strongly suggesting that Tc17 may be involved in the pathogenesis of ITP.²⁹

Considering the key role of Th17/Tc17 in immunity, as a main effector cytokine, IL-17 is believed to play a crucial role in inflammation by inducing activation of various proinflammatory cytokines, such as IL-1, IL-6, and interferon γ. Until now, although the exact mechanism of IL-17F in ITP is still unknown, IL-17F expression was elevated in splenocyte from ITP mice, and the genotype and IL-17F rs763780 G allele are significantly associated with the development of chronic ITP in a Japanese population, suggesting a role for IL-17F in the pathogenesis of ITP.²³ Thus, in the present study, we evaluated the association between IL-17F polymorphisms and ITP susceptibility in a Chinese Han population.

IL-17F rs763780 polymorphism causes a His-to-Arg substitution at amino acid 161 (H161R) of IL-17F and lacked the ability to activate the mitogen-activated protein kinase pathway, cytokine production, and chemokine production.¹⁸ Paradowska-Gorycka et al³⁰ discovered that the presence of the rare IL-17F G variant (rs763780) associated with lower expression of IL-17F and thus affect the disease susceptibility and activity of rheumatoid arthritis in the Polish population. A growing body of researchers found IL-17F rs763780 G and genotype GG to be associated with a decreased risk for many autoimmune diseases, including ITP.²³ For gene distribution frequency is correlated with ethnicity, in order to known the association of IL-17F rs763780 polymorphism and genetic suspect to Chinese patients with ITP, we investigated the genotype and allele frequencies of IL-17F rs763780 sites in a Chinese Han population. In accordance with Saitoh’s research, the frequency of G allele of IL-17F single nucleotide polymorphism (SNP) rs763780 was found to be significantly decreased in patients with ITP, suggested that the G allele has protective effect on the development of ITP. This is in accordance with 2 independent studies highlighted the possibility that IL-17F SNP might be an important regulator in ITP pathogenesis. However, the exact mechanisms by which IL-17F SNP modulates the susceptibility is still unknown, we speculated the carriers of G allele suppressed IL-17F expression and activity, thus further protected the development of ITP. Besides comparing the gene distribution between total patients with ITP and normal controls to well understand the contribution of IL-17F rs763780 polymorphism to ITP pathogenesis, we analyzed the distribution of genotype and alleles between normal controls and different subsets of patient with ITP, which were divided by different clinical parameters including first onset age, clinical responses to GCs, disease course, and gender. And consistent with previous research,²³ we found the frequency of G allele was decreased in patients with chronic ITP, implying the rare IL-17F G variant associated with disease development of ITP. In addition, in the gender-matched analysis, we observed an association of IL-17F rs763780 allele G with ITP in female, suggesting that the decreased distribution of protective allele may contribute to elevated morbidity of ITP in female. However, no significant association was detected between IL-17F polymorphism and GCs responses/first on-set age of ITP patients. Saitoh et al²³ also found patients with the IL-17F rs763780 AA genotype showed a severe thrombocytopenic state at diagnosis than those with the IL-17F rs763780 AG genotype. In our study, we could not get the exact platelet number at diagnosis because most patients were first diagnosed in other hospital, we cannot compare the number of platelet among the patients with ITP harboring different genotypes of alleles.

In general, the result of this investigation indicated that G allele of rs763780 was significantly associated with the susceptibility to ITP in the Chinese population. However, this research may have several limitations. It is worthwhile to point out how this SNP exerts its role to achieve pathogenesis of ITP. Besides, additional prospective studies with large samples and different ethnic populations are needed to evaluate the role of IL-17F gene polymorphism in patients with ITP in the future.

Footnotes

Authors’ Note

Huiyuan Li and Zeping Zhou contributed equally to this manuscript.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported in part by grants of National Natural Science Foundation of China (81270581, 81260091, 81300385, and 81470286), Tianjin Municipal Science and Technology Commission (14JCZDJC35100), Specialized Research Fund for the Doctoral Program of Higher Education (20131106120039), Peking Union Medical College Youth Fund and the Fundamental Research Funds for the Central Universities (3332013068), Yunnan Provincial Science and Technology Department-Kunming Medical University Joint Special Foundation (2013FB152), High-level health technical leader training plan of Yunnan Province (D-201216), and Young prospective academic and technical leader training plan of Yunnan Province (2013HB088).

References

Semple

. Immune pathophysiology of autoimmune thrombocytopenic purpura. Blood Rev. 2002;16(1):9–12.

Olsson

Andersson

Jernås

. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9(9):1123–1124.

Liu

Zhao

Poon

. Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol. 2007;78(2):139–143.

Ogawara

Handa

Morita

. High Th1/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura. Eur J Haematol. 2003;71(4):283–288.

Panitsas

Theodoropoulou

Kouraklis

. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood. 2004;103(7):2645–2647

Semple

Milev

Cosgrave

. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood. 1996;87(10):4245–4254.

Zhu

Zhao

. Profile of Th17 cytokines (IL-17, TGF-beta, IL-6) and Th1 cytokine (IFN-gamma) in patients with immune thrombocytopenic purpura. Ann Hematol. 2008;87(11):899–904.

Zhang

Zhu

Hou

. Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpura. Haematologica. 2009;94(9):1326–1329.

Zhan

Hua

. The ratio of Treg/Th17 cells correlates with the disease activity of primary immune thrombocytopenia. PLoS One. 2012;7(12):e50909.

10.

Rutitzky

Lopes da Rosa

Stadecker

. Severe CD4 T cell-mediated immunopathology in murine schistosomiasis is dependent on IL-12p40 and correlates with high levels of IL-17. J Immunol. 2005;175(6):3920–3926.

11.

Qian

Liu

Hartupee

. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat Immunol. 2007;8(3):247–256.

12.

Chang

Park

Dong

. Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J Biol Chem. 2006;281(47):35603–35607.

13.

Robak

Kulczycka-Siennicka

Gerlicz

. Correlations between concentrations of interleukin (IL)-17A, IL-17B and IL-17F, and endothelial cells and proangiogenic cytokines in systemic lupus erythematosus patients. Eur Cytokine Netw. 2013;24(1):60–68.

14.

Jain

Attur

Furer

. Increased Plasma IL-17F Levels in Rheumatoid Arthritis Patients Are Responsive to Methotrexate, Anti-TNF, and T Cell Costimulatory Modulation. Inflammation. 2015;38(1):180–186.

15.

Ota

Kawaguchi

Matsukura

. Potential involvement of IL-17F in asthma. J Immunol Res. 2014;2014:602846.

16.

Wang

. [The role of Th17 cells in immune thrombocytopenia mice models]. Zhonghua Xue Ye Xue Za Zhi. 2011;32(9):592–596.

17.

Moseley

Haudenschild

Rose

Reddi

. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 2003;14(2):155–174.

18.

Kawaguchi

Takahashi

Hizawa

. IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity. J Allergy Clin Immunol. 2006;117(4):795–801.

19.

Qian

Zhang

Zhou

. Association between polymorphisms in IL17F and male asthma in a Chinese population. J Investig Allergol Clin Immunol. 2012;22(4):257–263.

20.

Arisawa

Tahara

Shibata

. The influence of polymorphisms of interleukin-17A and interleukin-17F genes on the susceptibility to ulcerative colitis. J Clin Immunol. 2008;28(1):44–49.

21.

Seiderer

Elben

Diegelmann

. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn’s disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis. 2008;14(4):437–445.

22.

Wang

Zhai

Wang

. IL-17F but not IL-17A gene polymorphism confers risk to multiple sclerosis in a Chinese Han population. J Neurol Sci. 2014;342(1-2):133–136.

23.

Saitoh

Tsukamoto

Koiso

. Interleukin-17F gene polymorphism in patients with chronic immune thrombocytopenia. Eur J Haematol. 2011;87(3):253–258.

24.

Rodeghiero

Stasi

Gernsheimer

. Standardization of terminology, definitions and outcome criteria in immunethrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–2393.

25.

Zhu

Zhang

. Elevated interleukin-21 correlated to Th17 and Th1 cells in patients with immune thrombocytopenia. J Clin Immunol. 2010;30(2):253–259.

26.

Rocha

Souza

Rocha

. The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia. Haematologica. 2011;96(10):1560–1564.

27.

Guo

Chen

Zheng

. The role of Th17 cells in adult patients with chronic idiopathic thrombocytopenic purpura. Eur J Haematol. 2009;82(6):488–489.

28.

Sollazzo

Trabanelli

Curti

Vianelli

Lemoli

Catani

. Circulating CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia. Haematologica. 2011;96(4):632–634.

29.

Shan

. Increased number of Tc17 and correlation with Th17 cells in patients with immune thrombocytopenia. PLoS One. 2011;6(10):e26522.

30.

Paradowska-Gorycka

Wojtecka-Lukasik

Trefler

Wojciechowska

Lacki

Maslinski

. Association between IL-17F gene polymorphisms and susceptibility to and severity of rheumatoid arthritis (RA). Scand J Immunol. 2010;72(2):134–141.

Decreased Frequency of IL-17F rs763780 Site Allele G is Associated With Genetic Susceptibility to Immune Thrombocytopenia in a Chinese Population

Abstract

Keywords

Introduction

Methods

Patients

Extraction of Genomic DNA

Genotyping

Statistics

Results

Discussion

Footnotes

Authors’ Note

Declaration of Conflicting Interests

Funding

References